Antibodies Against Osteoporosis

  • Author: Antonia Niedobitek
  • Published: 16 September 2016
  • Copyright: Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
  • Source / Publisher: Open Biology/The Royal Society
thumbnail image: Antibodies Against Osteoporosis

Thomas D. Müller, University of Würzburg, Germany, and colleagues have crystallized an antibody that may potentially cure bone-eroding diseases such as osteoporosis. Current therapies can only prevent further bone resorption, whereas this strategy may help recover bone density.


The antibody targets a glycoprotein called sclerostin, a negative regulator of bone growth. The protein was identified as a potential target for the therapy of pathological bone resorption. Patients with sclerosteosis, a disease causing progressive bone overgrowth, lack sclerostin due to a mutation. In contrast, sclerostin inhibits healthy bone growth in patients with osteoporosis by binding to receptors involved in a signaling pathway that promotes bone growth.


In vitro experiments have shown that the developed antibody is capable of neutralizing sclerostin by blocking its receptor binding sites. First clinical trials show that the antibody causes increased bone mass in participants with osteoporosis. Further work will include the crystallization of the antibody together with sclerostin to analyze the molecular interaction in detail.


 

Article Views: 1480

Sign in Area

Please sign in below

Additional Sign In options

Please note that to comment on an article you must be registered and logged in.
Registration is for free, you may already be registered to receive, e.g., the newsletter. When you register on this website, please ensure you view our terms and conditions. All comments are subject to moderation.

Article Comments - To add a comment please sign in

Bookmark and Share

If you would like to reuse any content, in print or online, from ChemistryViews.org, please contact us first for permission. more


CONNECT:

ChemistryViews.org on Facebook

ChemistryViews.org on Twitter ChemistryViews.org on YouTube ChemistryViews.org on LinkedIn Sign up for our free newsletter


A product of ChemPubSoc Europe (16 European Chemical Societies)and Wiley-VCH